Logo
x

Search

Subscribe Now
China’s NMPA Approves Akeso's Ebdarokimab (IL-12/IL-23 Dual-Targeted mAb) for Moderate to Severe Plaque Psoriasis

China’s NMPA Approves Akeso's Ebdarokimab (IL-12/IL-23 Dual-Targeted mAb) for Moderate to Severe Plaque Psoriasis

  • April 18, 2025
BigHat Biosciences Collaborates with Eli Lilly to Advance AI-Driven Antibody Therapeutics

BigHat Biosciences Collaborates with Eli Lilly to Advance AI-Driven Antibody Therapeutics

  • April 18, 2025
Endevica Bio Reports the First Patient Dosing in P-II Study Evaluating TCMCB07 (B07)

Endevica Bio Reports the First Patient Dosing in P-II Study Evaluating TCMCB07 (B07)

  • April 18, 2025
Hikma Pharmaceuticals Acquires Novugen's US FDA ANDA Approved Trametinib

Hikma Pharmaceuticals Acquires Novugen's US FDA ANDA Approved Trametinib

  • April 18, 2025
The US FDA Accepts sBLA Priority Review for Regeneron's EYLEA HD in Macular Edema Following RVO and Monthly Dosing In Approved Indications

The US FDA Accepts sBLA Priority Review for Regeneron's EYLEA HD in Macular Edema Following RVO and Monthly Dosing In Approved Ind...

  • April 18, 2025
Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron

Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron

  • April 18, 2025
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.